Onconetix, Inc. (NASDAQ:ONCO) Short Interest Down 13.9% in January

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 107,197 shares, a drop of 13.9% from the January 15th total of 124,512 shares. Based on an average daily trading volume, of 212,934 shares, the days-to-cover ratio is currently 0.5 days. Currently, 7.0% of the shares of the company are short sold. Currently, 7.0% of the shares of the company are short sold. Based on an average daily trading volume, of 212,934 shares, the days-to-cover ratio is currently 0.5 days.

Onconetix Trading Down 3.2%

Shares of Onconetix stock opened at $0.76 on Thursday. The company has a 50-day moving average of $1.54 and a two-hundred day moving average of $2.49. The stock has a market cap of $1.18 million, a PE ratio of 0.07 and a beta of 3.45. Onconetix has a 12-month low of $0.62 and a 12-month high of $41.23.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned about 0.84% of Onconetix at the end of the most recent quarter. 23.89% of the stock is owned by institutional investors.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.